Friday, June 15, 2018 2:09:57 PM
2018-06-15 - Evaluation Update,
2018-06-14 - Comparison HIV-1 Anti-infective antibodies,
2018-06-14 - PRO 140 SC Combo about to arrive,
2018-06-14 - Pro 140 Related Publications,
2018-06-14 - Pro 140 Covering Scientists,
2018-06-12 - Insider Ownership,
2018-02-20 - Pro 140 Phase 2b/3 Pivotal PE Achieved,
2018-04-10 - CEO Letter to Investor
Calendar from March 2018 Presentation, PRs & Notes
- DONE: 6/9/18 CD02 Pivotal Phase 3 Endpoint Achieved (ASM Microbe late breaker) (Source: CYDY)
- 6/30: FDA meeting until end of June '18 to discus BLA/NDA presenting trial data, determining submission plan (Source: CYDY)
- 2Q18: Publication Studies – CD02 Combo Primary Endpoint Study (Source: CYDY)
- 7/30: Full CD02 Trial Data Disclosure. Should be finished towards end of June (assumption due ASM'18 poster + PR)
- 3Q18: BLA Submission for CD02 Combo (Source: CYDY)
- 4Q18: CD03 Phase 2b/3 Mono Investigative Trial Readout (probably later, CD03 completion around 2Q19) (Source: CYDY)
- 2018: HIV Breakthrough Therapy Designation (BTD) (Source: CYDY)
- 2019: CD02 HIV Combination Therapy Approval w/ BTD (Source: CYDY)
Recent CYDY News
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
